Detection of Sars-Cov-2At the Point of Care

Loeffelholz, Michael J.; Tang, Yi‐Wei

doi:10.4155/bio-2021-0078

Cited by 27 publications

(16 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In comparison to time-consuming and labor-intensive traditional diagnostic platforms, POC testing technologies feature rapid (typically results within minutes), high responsiveness and flexibility, low-cost advantages, and traceable testing (repeatable, real-time testing). In terms of SARS-CoV-2, the POC diagnostic setting is defined as physician offices, emergency departments, urgent care facilities, school health clinics, and pharmacies [ 18 ]. By highlighting the significance of exploiting POC diagnostic technologies for preventing and controlling pandemics in a timely manner, the global pandemic of COVID-19 has exposed clear discrepancies in POCT techniques, particularly the requirement for affordable portable diagnostic devices capable of offering fast and precise outcomes.…”

Section: Current Trends In Covid-19 Diagnostics: From Centralized Lab...mentioning

confidence: 99%

Recent advances of functional nucleic acid-based sensors for point-of-care detection of SARS-CoV-2

Zhang

Feng

et al. 2022

Microchim Acta

View full text Add to dashboard Cite

This review focuses on critical scientific barriers that the field of point-of-care (POC) testing of SARS-CoV-2 is facing and possible solutions to overcome these barriers using functional nucleic acid (FNA)-based technology. Beyond the summary of recent advances in FNA-based sensors for COVID-19 diagnostics, our goal is to outline how FNA might serve to overcome the scientific barriers that currently available diagnostic approaches are suffering. The first introductory section on the operationalization of the COVID-19 pandemic in historical view and its clinical features contextualizes essential SARS-CoV-2-specific biomarkers. The second part highlights three major scientific barriers for POC COVID-19 diagnosis, that is, the lack of a general method for (1) designing receptors of SARS-CoV-2 variants; (2) improving sensitivity to overcome false negatives; and (3) signal readout in resource-limited settings. The subsequent part provides fundamental insights into FNA and technical tricks to successfully achieve effective COVID-19 diagnosis by using in vitro selection of FNA to overcome receptor design barriers, combining FNA with multiple DNA signal amplification strategies to improve sensitivity, and interfacing FNA with portable analyzers to overcome signal readout barriers. This review concludes with an overview of further opportunities and emerging applications for FNA-based sensors against COVID-19. Graphical abstract

show abstract

Section: Current Trends In Covid-19 Diagnostics: From Centralized Lab...mentioning

confidence: 99%

Recent advances of functional nucleic acid-based sensors for point-of-care detection of SARS-CoV-2

Zhang

Feng

et al. 2022

Microchim Acta

View full text Add to dashboard Cite

show abstract

“…Here, the benefit of decoupling analysis automation from peripheral software functions such as dashboarding, monitoring, and reporting allowed new tools to be deployed to automatically identify samples that potentially were affected due to proximity to highly positive wells and needed to be flagged for retest, maintaining TaT for unaffected samples. Now, well into the pandemic, decentralized testing initiatives, reinforcement of regional networks of clinical laboratories, installation of mobile laboratories [14] and point-ofcare testing [15,16], and the adoption of different laboratory technologies [15,[17][18][19] will allow to further reduce TaT, and recent initiatives will soon lead to turnaround times below the hour.…”

Section: Maintaining Tat With Growing Volumesmentioning

confidence: 99%

Reliable and Scalable SARS-CoV-2 qPCR Testing at a High Sample Throughput: Lessons Learned from the Belgian Initiative

Vooren¹,

Grayson²,

Ranst

et al. 2022

Life

View full text Add to dashboard Cite

We present our approach to rapidly establishing a standardized, multi-site, nation-wide COVID-19 screening program in Belgium. Under auspices of a federal government Task Force responsible for upscaling the country’s testing capacity, we were able to set up a national testing initiative with readily available resources, putting in place a robust, validated, high-throughput, and decentralized qPCR molecular testing platform with embedded proficiency testing. We demonstrate how during an acute scarcity of equipment, kits, reagents, personnel, protective equipment, and sterile plastic supplies, we introduced an approach to rapidly build a reliable, validated, high-volume, high-confidence workflow based on heterogeneous instrumentation and diverse assays, assay components, and protocols. The workflow was set up with continuous quality control monitoring, tied together through a clinical-grade information management platform for automated data analysis, real-time result reporting across different participating sites, qc monitoring, and making result data available to the requesting physician and the patient. In this overview, we address challenges in optimizing high-throughput cross-laboratory workflows with minimal manual intervention through software, instrument and assay validation and standardization, and a process for harmonized result reporting and nation-level infection statistics monitoring across the disparate testing methodologies and workflows, necessitated by a rapid scale-up as a response to the pandemic.

show abstract

“…POC testing can be performed in a variety of settings, including physicians’ offices, emergency rooms, urgent care facilities, school clinics, and pharmacies [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Validation of a quantitative lateral flow immunoassay (LFIA)-based point-of-care (POC) rapid test for SARS-CoV-2 neutralizing antibodies

et al. 2022

View full text Add to dashboard Cite

With the widespread use of coronavirus disease 2019 (COVID-19) vaccines, a rapid and reliable method to detect SARS-CoV-2 neutralizing antibodies (NAbs) is extremely important for monitoring vaccine effectiveness and immunity in the population. The purpose of this study was to evaluate the performance of the RapiRead™ reader and the TestNOW™ COVID-19 NAb rapid point-of-care (POC) test for quantitative measurement of antibodies against the spike protein receptor-binding domain of severe respiratory syndrome coronavirus 2 (SARS-CoV-2) in different biological matrices compared to chemiluminescence immunoassay (CLIA) methods. Ninety-four samples were collected and analyzed using a RapiRead™ reader and TestNOW™ COVID-19 NAb kits for detecting neutralizing antibodies, and then using two CLIAs. The data were compared statistically using the Kruskal-Wallis test for more than two groups or the Mann-Whitney test for two groups. Specificity and sensitivity were evaluated using a receiver operating characteristic (ROC) curve. Good correlation was observed between the rapid lateral flow immunoassay (LFIA) test system and both CLIA methods. RapiRead™ reader/TestNOW™ COVID-19 NAb vs. Maglumi: correlation coefficient (r) = 0.728 for all patients; r = 0.841 for vaccinated patients. RapiRead™ reader/TestNOW™ COVID-19 NAb vs. Mindray: r = 0.6394 in all patients; r = 0.8724 in vaccinated patients. The time stability of the POC serological test was also assessed considering two times of reading, 12 and 14 minutes. The data revealed no significant differences. The use of a RapiRead™ reader and TestNOW™ COVID-19 NAb assay is a quantitative, rapid, and valid method for detecting SARS-CoV-2 neutralizing antibodies and could be a useful tool for screening studies of SARS-CoV-2 infection and assessing the efficacy of vaccines in a non-laboratory context.

show abstract

Detection of Sars-Cov-2At the Point of Care

Cited by 27 publications

References 100 publications

Recent advances of functional nucleic acid-based sensors for point-of-care detection of SARS-CoV-2

Recent advances of functional nucleic acid-based sensors for point-of-care detection of SARS-CoV-2

Reliable and Scalable SARS-CoV-2 qPCR Testing at a High Sample Throughput: Lessons Learned from the Belgian Initiative

Validation of a quantitative lateral flow immunoassay (LFIA)-based point-of-care (POC) rapid test for SARS-CoV-2 neutralizing antibodies

Contact Info

Product

Resources

About